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Background: The human genome encodes many long non-coding RNAs (lncRNAs). However, their biological
functions, molecular mechanisms, and the prognostic value associated with pancreatic ductal adenocarcinoma
(PDAC) remain to be elucidated. Here, we identify a fundamental role for the lncRNA HOXA transcript at the distal
tip (HOTTIP) in the progression and chemoresistance of PDAC.
Methods: High-throughput microarrays were performed to detect the expression profiles of lncRNAs and
messenger RNAs in eight human PDAC tissues and four pancreatic tissues. Quantitative real-time PCR was used to
determine the levels of HOTTIP and HOXA13 transcripts in PDAC cell lines and 90 PDAC samples from patients.
HPDE6 cells (immortalized human pancreatic ductal epithelial cells) and corresponding adjacent non-neoplastic
tissues were used as controls, respectively. The functions of HOTTIP and HOXA13 in cell proliferation, invasion, and
epithelial-mesenchymal transition were evaluated by targeted knockdown in vitro. CCK-8 assays, colony formation
assays, and xenografts in nude mice were used to investigate whether targeted silencing of HOTTIP could sensitize
pancreatic cancer cells to gemcitabine. Immunohistochemistry was performed to investigate the relationship
between HOXA13 expression and patient outcome.
Results: Microarray analyses revealed that HOTTIP was one of the most significantly upregulated lncRNAs in PDAC
tissues compared with pancreatic tissues. Quantitative PCR further verified that HOTTIP levels were increased in
PDAC cell lines and patient samples compared with controls. Functionally, HOTTIP silencing resulted in proliferation
arrest by altering cell-cycle progression, and impaired cell invasion by inhibiting epithelial-mesenchymal transition
in pancreatic cancer. Additionally, inhibition of HOTTIP potentiated the antitumor effects of gemcitabine in vitro and
in vivo. Furthermore, knockdown of HOXA13 by RNA interference (siHOXA13) revealed that HOTTIP promoted PDAC
cell proliferation, invasion, and chemoresistance, at least partly through regulating HOXA13. Immunohistochemistry
results revealed that higher HOXA13 expression was correlated with lymph node metastasis, poor histological
differentiation, and decreased overall survival in PDAC patients.
Conclusions: As a crucial tumor promoter, HOTTIP promotes cell proliferation, invasion, and chemoresistance by
modulating HOXA13. Therefore, the HOTTIP/HOXA13 axis is a potential therapeutic target and molecular biomarker
for PDAC.
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Pancreatic ductal adenocarcinoma (PDAC), which ac-
counts for more than 80% of pancreatic cancer cases, is
one of the most malignant diseases world-wide. Surgical
resection offers the best chance for a possible cure; how-
ever, because of the absence of specific symptoms and
the lack of early detection, PDAC is usually diagnosed at
an advanced stage. Thus, only 10–20% of diagnosed
patients present with potentially resectable pancreatic
cancer [1,2]. Chemotherapy also plays a critical role in
improving symptoms and prolonging overall survival of
PDAC patients. However, PDAC is highly resistant to
chemotherapy, including gemcitabine treatment, which
is generally regarded as the first-line chemotherapy regi-
men [3]. In the past decades, despite constant efforts to
improve the diagnosis and treatment of PDAC, this dev-
astating disease still has a dismal prognosis [4-7]. The
roadblocks to major progress are predominantly related
to the sophisticated biology and regulatory mechanisms
underlying this disease. Hence, a better understanding of
the genetic alterations and molecular mechanisms in-
volved in PDAC development and chemoresistance will
facilitate the identification of novel diagnostic and thera-
peutic targets [8].
Studies on human genomes have demonstrated that
non-coding RNAs (ncRNAs), which do not encode pro-
teins, account for more than 90% of the transcriptome
[9]. The functions of a number of ncRNAs have been
characterized, and it is evident that they play crucial
roles in the regulation of gene expression, splicing,
epigenetic control, chromatin structure, and nuclear
transport [10-14]. Among the various classes of ncRNAs,
microRNAs (18–200 nucleotides) have been extensively
studied, and it has been shown that >1000 microRNAs
regulate up to 30% of all protein-encoding genes [13-16].
Additionally, long non-coding RNAs (lncRNAs), defined
as non-coding RNAs more than 200 nucleotides in length,
are gaining prominence because of their emerging roles in
the regulation of critical cellular functions, including the
modulation of apoptosis and proliferation, reprogramming
of human-induced pluripotent stem cells, tissue differenti-
ation, and as markers of cell fate [17-21]. Importantly, a
number of cancer-specific lncRNAs have been identified,
which may be employed as novel biomarkers for diagnosis
and as therapy targets [22,23].
The HOTTIP lncRNA, located at the 5′ end of the
HOXA cluster, was recently functionally characterized
[24]. Consistent with its genomic position, HOTTIP was
significantly expressed in anatomically distal human fibro-
blasts [24]. The activity of HOTTIP is a result of its inter-
action with the WDR5/MLL complex, which enhances
histone H3 lysine 4 trimethylation to activate the expres-
sion of multiple 5′ HOXA genes [24]. Recently, it was
reported that HOTTIP is a negative prognostic factor inpatients with liver cancer, and increased HOTTIP expres-
sion was associated with enhanced liver cancer metastasis
[25]. In addition, HOTTIP expression is linked to the for-
mation of chemical and ultraviolet radiation-induced skin
cancer [26]. However, the underlying role and mechanism
of HOTTIP in PDAC remain unknown. The focus of this
study was to identify the roles that HOTTIP plays in
PDAC, and to uncover the potential mechanisms by
which HOTTIP contributes to disease pathogenesis.
In this study, we explored the role of HOTTIP in the
regulation of proliferation, invasion, and chemoresistance
of pancreatic cancer. We show that targeted silencing of
HOTTIP impairs proliferation, invasion, and epithelial-
mesenchymal transition ability. Moreover, for the first
time, we identify an important role for HOTTIP in gemci-
tabine chemoresistance in pancreatic cancer cells. Further-
more, we demonstrate that HOXA13, which is located in
physical contiguity with HOTTIP, is a significant target of
HOTTIP, and is involved in the progression of PDAC.
Methods
Cell culture
The human pancreatic cancer cell lines, PANC-1, MIA
PaCa-2, Capan-2, SW1990, and BxPC-3, were purchased
from the American Type Culture Collection and grown
in complete growth medium as recommended by the
manufacturer, supplemented with 10% FBS and 1% peni-
cillin/streptomycin. HPDE6 cells (immortalized human
pancreatic ductal epithelial cells) were obtained from Dr.
SN Zhang (Sun Yat-Sen University, Guangdong, China).
All cells were cultured in a humidified 5% CO2 incuba-
tor at 37°C.
Microarray analysis
Transcriptomic analysis was performed using Arraystar
human lncRNA microarrays, V3 (Agilent,Santa Clara,
USA), which target 27958 Entrez protein-coding genes
and 7419 lncRNAs. Total RNA was extracted and mRNA
was purified using the mRNA-ONLY™ Eukaryotic mRNA
Isolation Kit (Epicentre). Total RNA was fragmented, la-
beled (One-Color, Cy3, Agilent), purified, and hybridized
with probes in Hybridization Chamber gasket slides
(Agilent). The slides were then washed and scanned
with an Agilent Microarray Scanner. The raw data were
extracted with Agilent Feature Extraction software (Agi-
lent). This software uses the robust multi-array average
algorithm to adjust the background signals. Normalized
data were obtained after performing the quantile method
of intra-microarray normalization and the median method
of baseline transformation between the microarrays.
Differentially expressed genes with a raw expression level
of >400 in more than 4 out of the 12 samples used for
profiling were extracted and ordered by p-value. Genes
with the highest top 10 p-values were selected for
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mitted to the Gene Expression Omnibus public database
at the National Center for Biotechnology Information
(accession number: GSE61166, http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=gse61166).
RNA isolation and quantitative real-time Reverse
Transcription-PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol re-
agent (Invitrogen, San Diego, CA, USA) according to the
manufacturer’s instructions. qRT-PCR was performed
for HOTTIP, HOXA13, and EMT markers (E-cadherin,
Vimentin, and Snai1), with GAPDH as an internal con-
trol. RNA was extracted from frozen pancreatic cancer
tissues and their corresponding non-neoplastic tissues
using TRIzol reagent (Invitrogen) and qRT-PCR was per-
formed for HOTTIP and HOXA13 mRNA using β-actin
as an internal control. Total RNA was then converted to
cDNA by reverse transcription using oligodT primers and
SuperScript II reverse transcriptase (Invitrogen). For qRT-
PCR, three replicates of each sample were amplified in a
20-μL reaction mixture containing SYBR Green reaction
mix (Qiagen,Germany) and 0.5 mM of primer, and
analyzed using a Roche Light-Cycler (Roche, Basel,
Switzerland). The relative gene expression in cells was
determined using the comparative delta-delta CT
method (2-ΔΔCt) and the fold change in gene expression
of tissues was calculated using the standard ΔΔCT
method.
HOTTIP and HOXA13 knockdown
The following HOTTIP shRNA and scrambled control
shRNA were inserted into the pLVX-tdTomato-Puro
lentiviral vector (Open Biosystems, Rockford, IL ). HOT
TIP shRNA forward, 5′ -GATCCGCTGCTTTAGAGCC
ACATATTCAAGAGATATGTGGCTCTAAAGCAGCT
TTTTTCTCGAGG-3′ and reverse, 5′-AATTCCTCG
AGAAAAAAGCTGCTTTAGAGCCACATATCTCTT
GAATATGTGGCTCTAAAGCAGCG-3′. Scrambled con-
trol shRNA, forward, 5′-CCGGTTTCTCCGAACGTGT
CACGTCTCGAGACGTGACACGTTCGGAGAATTTT
TG- 3′ and reverse, 5′ -AATTCAAAAAGTTCTCCG
AACGTGTCACGTCTCGAGACGTGACACGTTCGG
AGAA- 3′.
shRNA lentivirus was used to generate stable HOT-
TIP-knockdown cells. Lentiviral particles were produced
by transfecting 239 T cells. Viral supernatants were col-
lected 72 h after transfection, and particles were concen-
trated using a LentiX™ Concentrator overnight at 4°C
(Clontech, Mountain View, CA, USA), and aliquots were
stored at −80°C. Viral titers of concentrated particles
were 1.1 × 108 TU/mL. SW1990 and MIA PaCa-2 cells
(5 × 105 cells/well ) were seeded in six-well culture plates
and maintained in DMEM with 10% FBS for 24 h priorto infection. For screening, puromycin ( 10 μg/mL ) was
added to the medium containing HOTTIP knockdown
cells 72 h after infection.
The medium was then replaced every 2 days for
2–3 weeks.
SW1990 and MIA PaCa-2 cells were transfected with
siRNAs targeting HOXA13 mRNA (# SIC002-1NMOL,





and an off-target negative control (# SIC007MSDS, Sigma
Aldrich), using Lipofectamine RNAiMAX (Invitrogen,
Grand Island, NY, USA).
Cell growth and cell-cycle assays
For cell growth assay, SW1990 or MIA PaCa-2 cells with
HOTTIP or HOXA13 knockdown were seeded in 96-
well plates (1 × 103 cells per well) and pre-incubated at
37°C, 5% CO2, in a humidified atmosphere for 0, 24, 48
or 96 h. Counting Kit-8 kit (CCK-8) solution (10 μL,
Dojindo Molecular Technologies, Kyushu, Japan) was
then added to each well and the plate was incubated for
4 h at 37°C, 5% CO2, in a humidified atmosphere. The
absorbance was measured at 450 nm using a microplate
reader.
For cell-cycle analysis, SW1990 or MIA PaCa-2 cells
(5 × 104 cells) with HOTTIP knockdown were collected
and washed three times with PBS. Cells were then incu-
bated in propidium iodide (PI) staining solution (RNase
A 100 ug/ml and PI 500 ug/ml) for 30 min at 4°C, and
cells were analyzed by flow cytometry.
Boyden chamber cell invasion
Invasion assays were performed using the BD Biocoat
Matrigel Invasion Chamber (8 μm; BD Biosciences, San
Jose, CA, USA) following the manufacturer’s protocol.
After HOTTIP or HOXA13 knockdown, 1 × 104 cells
were plated in the upper chamber. The bottom chamber
contained medium with 10% FBS to stimulate invasion.
After 48 h, the bottom chamber insert was stained with
0.1% crystal violet, and cells were counted by photograph-
ing the membrane using a microscope and a × 20 objective
lens. Each assay was conducted at least three times.
Western blot analysis
Cells were washed in PBS and lysed with RIPA buffer
(Invitrogen), and a bicinchoninic acid protein assay kit
(Pierce, Rockford, IL, USA) was used to calculate the
protein concentration of each sample. Equivalent amounts
of proteins were separated by SDS-PAGE and transferred
to polyvinylidene fluoride membranes for immunoblot-
ting. The membranes were blocked in 5% fat-free milk for
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incubated with the following primary antibodies: rabbit
anti-human HOXA13 antibody (1:500, #ab26084, Abcam,
Cambridge, MA, USA), rabbit anti-human E-cadherin
(1:1000, #ab40772, Abcam), rabbit anti-human Vimen-
tin (1:1000; #ab92547, Abcam), rabbit anti-human Snai1
(1:1000, #ab180714, Abcam), and rabbit anti-human
GAPDH antibody (1:1000, #ab18162, Abcam). GAPDH
was used as a loading control. Horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling Technology,
Boston, USA) and an ECL chemiluminescence kit (Pierce)
were used to detect bound antibody.Immunofluorescence (IF) analysis
Following introduction of SW1990 cells with shRNA or
siRNA, cells were cultured to confluency on uncoated
glass cover slips for 24 h, and fixed in 4% paraformalde-
hyde at room temperature for 15 min. After washing
with PBS, the adherent cell monolayer was permeabli-
lized with 0.1% Triton X-100 in PBS and blocked for 1 h
with 10% normal goat or donkey serum in 1% BSA/
PBS, followed by overnight incubation at 4°C with
primary antibodies: rabbit anti-human E-cadherin
(1:100, #ab40772, Abcam), rabbit anti-human Vimen-
tin (1:100; #ab92547, Abcam), rabbit anti-human Snai1
(1:100, #ab180714, Abcam), rabbit anti-human HOXA13
antibody (1:100, #sc-133669, Santa Cruz Biotechnology
Inc, Santa Cruz, CA, USA). After washing with PBS, cells
were incubated with the Alexa 488-conjugated sec-
ondary antibody (#A20181, Molecular Probes, Leiden,
The Netherlands) for 1 h. Cells were then washed three
times with PBS and mounted in Vectashield containing
DAPI (#ab104139, Abcam). The slides were analyzed
using a confocal laser scan microscope.In vitro chemosensitivity assay
SW1990 cells transduceded with shHOTTIP or control
shRNA were seeded (5 × 103/well) in 96-well plates.
After incubation for 24 h, varying concentrations of
gemcitabine (Lilly, Indianapolis, IN, USA) were added to
the cells. After 72 h incubation in a humidified atmos-
phere containing 5% CO2, 10 μL CCK-8 reagent was
added to each well and cells were incubated for 4 h. The
absorbance of each well was determined using an ELISA
reader (Wellscan MK3; Labsystems Dragon, Finland) at
a wavelength of 450 nm.
For colony formation, SW1990 cells transduced with
shHOTTIP or control shRNA were seeded (500 cells/well)
in six-well plates overnight and gemcitabine (10 μM) or
PBS (100 μL) was added to the cultured cells on the sec-
ond day. After 14 days, the culture medium was removed,
and cells were briefly rinsed with PBS. The cells were then
fixed with 4% paraformaldehyde and stained with 0.1%crystal violet, and colonies were counted by visual
inspection.
In vivo chemosensitivity assays
All experiments involving animals were conducted accord-
ing to the institutional guidelines of Guangdong Province
and were approved by the institutional guidelines of
Guangdong Province and by the Use Committee for
Animal Care. BALB/c nude mice (4–6 weeks old) were
randomly separated into the following groups (n = 4
mice per group): (a) SW1990-shcontrol, PBS; (b) SW1990-
shHOTTIP, PBS; (c) SW1990-shcontrol, gemcitabine; (d)
SW1990-shHOTTIP, gemcitabine. Each mouse was inocu-
lated subcutaneously in the dorsal flank with SW1990 cells
(3 × 106 cells/mouse) stably transduced with shHOTTIP
or control shRNA. When the xenografts reached a
mean size of 0.1–0.15 cm2 on the 5th day after cell
injection, the mice received gemcitabine (120 mg/kg)
or PBS (100 μL) via intraperitoneal (i.p.) injection
once every 3 days. All groups were treated five times.
The tumors were measured every 3–4 days, and tumor
volume was calculated using the following formula: vol-
ume = (L ×W2)/2, where L and W are the longest and
shortest diameters, respectively. The mice were sacrificed
when the average L of any group reached approximately
1 cm.
Immunohistochemistry staining and scoring
Paraffin-embedded samples of primary carcinomas were
stained for HOXA13. Sections were deparaffinized in xylene
and rehydrated in a graded series of ethanol, followed by
heat-induced epitope retrieval in citrate buffer (pH = 6.0).
Antigen retrieval was performed in 10 mmol/L citrate buf-
fer (pH = 6.0) in a microwave oven for 15 min. The activity
of endogenous peroxidases was blocked by the addition of
3% hydrogen peroxide for 10 min at room temperature.
Rabbit HOXA13 antibody (#ab26084, Abcam, 1:100)
was applied overnight at 4°C, and after washing three
times in PBS, sections were immunostained with a
goat anti-rabbit secondary antibody (#191866, Abcam,
0.2 ug/ml) for 1 h at 37°C. The slides were incubated
with streptavidin-HRP conjugate complex for 45 min
at 37°C. After rinsing three times in PBS, the sections
were developed with 3,3′-diaminobenzidine. Sections
were counterstained with hematoxylin. Sections of skin
tissues known to stain positive for HOXA13 were used as
positive controls, and normal goat serum and PBS
substituting the primary antibody were used as negative
controls.
For evaluation and grading of HOXA13 staining results,
a scoring criterion previously described by Ohara et al.
[27] was used. Briefly, the staining intensity of HOXA13
was graded on a scale of 0–3 (0, none; 1, weak; 2, inter-
mediate; and 3, strong). HOXA13 expression was assessed
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for no staining; 1 point for <25% staining; 2 points
for 26–50% staining; 3 points for 51–75% staining;
and 4 points for 76–100% staining. The total score was
calculated as the product of the scores for the intensity
and positive rate of staining. Staining was assessed by two
pathologists according to the scoring criteria. Cases with
discrepancies were jointly reevaluated until a consensus
was reached.
Patient samples
All samples were obtained from patients undergoing
resection of the pancreas at the Sun Yat-Sen MemorialFigure 1 HOTTIP levels are up-regulated in PDAC tissues and cell line
(PDAC) and four cases of chronic pancreatitis were used for microarray analys
(n = 8) compared with chronic pancreatitis tissues (n = 4) are shown. (B) HOTT
adjacent non-neoplastic tissues was examined via quantitative reverse tra
internal control. Relative gene expression was determined using the comp
HOTTIP expression was evaluated in five pancreatic cancer cell lines compare
mRNA levels were normalized to GAPDH. Data represent the mean ± s.d. fromHospital between 2009 and 2014. Informed consent was
obtained from all patients before sample collection. All
patients had a clear histological diagnosis. Patient speci-
mens and related clinicopathological data, including
complete follow-up, were obtained from the Institute of
Pathology and from the Department of Pancreaticobili-
ary, Sun Yat-Sen Memorial Hospital. All patients in this
study met the following criteria: PDAC diagnosis verified
by pathological examination, paraffin-embedded tissues
were well stored and qualified for serial section, the corre-
sponding tumor tissues and the paired non-tumor tissues
were stored in liquid nitrogen immediately following sur-
gical removal, no anticancer treatments given befores. (A) Total RNA from eight cases of pancreatic ductal adenocarcinoma
is. Long noncoding RNAs (lncRNAs) upregulated >10-fold in PDAC tissues
IP expression levels in 90 paired PDAC tissues and corresponding
nscription-polymerase chain reaction (qRT-PCR). β-actin was used as
arative delta-delta CT method, and data are presented as △△Ct. (C)
d with immortalized human ductal epithelial cells by qRT-PCR. HOTTIP
three independent experiments. **p < 0.01, Student’s t-test.
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logic and follow-up data.
Statistical analysis
Statistical analyses were performed using SPSS Statistics
16.0 (IBM Chicago, IL, USA). The chi-square test (X2
test), Fisher’s exact test for non-parametric variables, and
Student’s t test for parametric variables were used (two-
tailed). Differences in patient survival were assessed using
the Kaplan–Meier method and analyzed using the log-
rank test in a univariate analysis. All tests were two-sided,
and a p < 0.05 was considered statistically significant.Figure 2 HOTTIP knockdown inhibits cell growth and cell cycle in PD
RNA-stably transduced PDAC cell lines. Relative gene expression was deter
MIA PaCa-2 and SW1990 cells were infected with control shRNA or an shRN
indicated time points after transfection using CCK-8 assays. (D) (E) MIA PaC
against HOTTIP as indicated. The cell-cycle distribution was assessed follow
from three independent experiments. **p < 0.01, Student’s t-test.Results
The expression of HOTTIP is increased in PDAC tissues
and cell lines
To identify lncRNAs overexpressed in PDAC, we per-
formed gene expression array analysis on eight PDAC
tissues and four chronic pancreatitis clinical samples.
Twenty seven lncRNAs including HOTTIP, were upreg-
ulated more than 10-fold in PDAC compared with
chronic pancreatitis tissues (Figure 1A). To further val-
idate these results, we analyzed HOTTIP expression in
90 paired resected samples by qRT-PCR. Compared with
adjacent non-tumor tissues, HOTTIP was up-regulatedAC cells. (A) The efficiency of HOTTIP silencing in short hairpin
mined using the comparative delta-delta CT method (2-ΔΔCt). (B) (C)
A against HOTTIP as indicated. Cell viability was determined at the
a-2 and SW1990 cells were tansduced with control shRNA or an shRNA
ing transduction by flow cytometry. Data represent the mean ± s.d.
Figure 3 (See legend on next page.)
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Figure 3 HOTTIP knockdown inhibits PDAC cell invasion and epithelial-mesenchymal transition (EMT). (A) MIA PaCa-2 and SW1990 cells
were transduced with control shRNA or an shRNA against HOTTIP as indicated, and invasion assays were performed. Representative photos of
invasive cells on the membrane are shown. (B) The effect of HOTTIP knockdown on the invasion ability of MIA PaCa-2 cells and SW1990 cells was
quantified by counting the number invasive cells. (C) (D) The effect of HOTTIP knockdown on expression of E-cadherin, Vimentin, and Snail 1 was
evaluated by qRT-PCR. (E) (F) The effect of HOTTIP-knockdown on E-cadherin, Vimentin, and Snail 1 protein levels was confirmed by western
blotting. (G) (H) (I) Immunofluorescence staining for the EMT makers in SW1990 cells. Data represent the mean ± s.d. from three independent
experiments. **p < 0.01, Student’s t-test.
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expression of HOTTIP in five pancreatic cancer-derived
cell lines (PANC-1, Capan-2, MIA PaCa-2, BxPC-3, and
SW1990) and in immortalized human pancreatic ductal
epithelial cells (HPDE6) by qRT-PCR. In accordance with
the above findings, all pancreatic cancer cell lines ex-
hibited higher levels of HOTTIP compared with the
non-tumoral pancreatic cell line, HPDE6, with the high-
est expression observed in SW1990 cells (Figure 1C).
HOTTIP regulates cell growth and the cell cycle in PDAC
cells
To investigate the role of HOTTIP in PDAC progres-
sion, we first established stable HOTTIP knockdown
SW1990 and MIA PaCa-2 cell lines by retrovirus infec-
tion (Figure 2A). CCK-8 assays revealed that depletion
of HOTTIP reduced cell proliferation compared with
shControl in both cell lines (Figure 2B,C). To further in-
vestigate the growth inhibition observed following HOT-
TIP knockdown, we compared the cell-cycle profiles of
HOTTIP knockdown cells and controls by flow cytome-
try. Suppression of HOTTIP led to a decrease in the
number of cells in the S-phase and an increase in the
percentage of cells in the G0/G1 phase (Figure 2D, 2E).
HOTTIP regulates PDAC cell invasion and Epithelial-
Mesenchymal Transition (EMT)
We next investigated the effect of HOTTIP on PDAC
cell invasion. We first examined the effect of HOTTIP
stable knockdown on SW1990 and MIA PaCa-2 cell
invasion using transwell assays. HOTTIP knockdown
dramatically reduced the invasion of SW1990 and MIA
PaCa-2 cells (Figure 3A). Quantification of invading cells
revealed a significant decrease in the number of in-
vading cells for both cell lines after HOTTIP knockdown
(Figure 3B). Because EMT is vital for PDAC cell invasion,
we next examined whether silencing HOTTIP expression
inhibited mesenchymal features. As expected, HOTTIP
knockdown decreased the expression of Vimentin and
Snai1 and increased E-cadherin expression, at both the
mRNA (Figure 3C,D) and protein (Figure 3E,F) levels.
Therefore, inhibition of HOTTIP in SW1990 and MIA
PaCa-2 cells changed the cell morphology from a mesen-
chymal to a more epithelial phenotype (Figure 3G,H,I).HOTTIP knockdown enhances the chemosensitivity of
human pancreatic cancer cells to gemcitabine in vitro and
in vivo
Innate or acquired resistance to chemotherapy is a hall-
mark of PDAC. Considering the effect of HOTTIP on
cell proliferation, cell cycle, and EMT identified above,
we further tested whether down-regulation of HOTTIP
impaired the resistance of PDAC cells to gemcitabine.
SW1990 cells stably knocked down for HOTTIP expression
(SW1990-shHOTTIP) or infected with control shRNA
(SW1990-shcontrol) were exposed to 0.1, 1, and 10 μM
gemcitabine for 72 h, and IC50 values were calculated using
the CCK-8 cytotoxicity assay (Figure 4A,B). Compared with
SW1990 control cells, SW1990-shHOTTIP knockdown
cells exhibited much slower growth (Figure 4A) and a
lower IC50 for gemcitabine (1.956 ± 0.353 μM vs 5.808 ±
1.361 μM) (Figure 4B). Colony formation was next
examined using SW1990 cells stably transduced with
shHOTTIP or control shRNA, following exposure to
either gemcitabine or PBS for 14 days. Colony growth
was significantly inhibited after treatment with gemcita-
bine (n = 4) or following HOTTIP-knockdown, compared
with control. Moreover, combined gemcitabine treatment
and HOTTIP knockdown led to a significant reduction in
colony formation compared with either treatment alone
or the control (Figure 4C).
The ability of HOTTIP to confer chemoresistance in
PDAC was further examined using an in vivo tumor
model. As shown in Figure 4D and E, tumor growth was
inhibited in nude mice treated with gemcitabine alone
(n = 4) or following HOTTIP-knockdown (n = 4) com-
pared with the controls (n = 4). Tumor growth rate was
most significantly inhibited in mice following combined
gemcitabine treatment and HOTTIP knockdown. At
21 days, the mean tumor volume for the gemcitabine
group and the HOTTIP-knockdown group was mark-
edly smaller than that of the control group (265.0 ±
34.31 mm3, 277.9 ± 51.42 mm3, and 687 ± 71.26 mm3, re-
spectively) (Figure 4F). Furthermore, combined treatment
with gemcitabine and HOTTIP knockdown (n = 4) led
to an even further reduction in tumor volume (107 ±
34.31 mm3). As expected, the tumor weight at the end of
the gemcitabine treatment period showed a similar trend
(Figure 4G).
Figure 4 (See legend on next page.)
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Figure 4 HOTTIP knockdown enhances the chemosensitivity of human pancreatic cancer cells to gemcitabine in vitro and in vivo. (A)
SW1990 cells were infected with control shRNA or an shRNA against HOTTIP as indicated, and then treated with gemcitabine (0.1, 1, or 10 μM)
for 72 h. Cell survival rates were then measured using CCK-8 assays. The values are presented as the means ± s.d. **P < 0.01. (B) The effect of
HOTTIP suppression on the IC50 of SW1990 cells was calculated. (C) SW1990 cells were infected with control shRNA or shRNA against HOTTIP as
indicated and then treated with gemcitabine (10 μM) or PBS (100 μL) for 14 days. Colony formation on plastic was then assessed. Representative
plates are shown. The number of colonies on each plate was calculated using Image J. The first group was set as the control group, and served
as the baseline for colony number normalization. (D) SW1990 cells were transduced with control shRNA or shRNA against HOTTIP as indicated.
Cells (3 × 105) were then subcutaneously injected into mice, and gemcitabine or PBS were injected intraperitoneally once every 3 days for five
cycles. Representative images of tumor-bearing mice are shown. (E) Images of tumors from all mice in each group. (F) Tumor volumes were
measured on the indicated days. (G) Tumor weights were determined. In vitro data are represented as the mean ± s.d. from three independent
experiments. **p < 0.01, Student’s t-test.
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Because emerging evidence suggests that certain mem-
bers of the HOXA cluster are involved in cancer progres-
sion, we hypothesized that HOTTIP might regulate the
biological behavior of PDAC via regulation of the HOXA
cluster. To confirm this hypothesis, we first evaluated
the effect of HOTTIP knockdown on the expression of
5′ HOXA genes (HOXA7, HOXA9, HOXA10, HOXA11,
HOXA13) by qRT-PCR. In SW1990 and MIA PaCa-2
cells, depletion of HOTTIP inhibited the expression of
these genes to varying degrees, with the strongest inhib-
ition observed for HOXA13 (Figure 5A,B). Inhibition of
HOXA13 levels was further confirmed by western blot-
ting (Figure 5C). As expected, decreased nuclear im-
munofluorescence staining of HOXA13 was observed in
SW1990 cells (Figure 5D). To confirm the expression
and association between HOTTIP and HOXA13 expres-
sion levels, we evaluated the expression of HOXA13 in
90 paired resected samples, which included the eight
PDAC samples used for the array analysis (Additional
file 1: Figure S1A), and the presented panel of cell lines
(Additional file 1: Figure S1B) by qRT-PCR. We observed
enhanced expression of HOXA13 levels both in tumor
tissues and cell lines (Figure 5E, Additional file 1: Figure
S1B). Furthermore, we also observed a positive correlation
between HOTTIP and HOXA13 expression levels both in
cancer cell lines (Additional file 1: Figure S1C) and clinical
samples (Figure 5F).
HOXA13 partly mediates the effect of HOTTIP on PDAC biology
In the above section, we demonstrated that the strongest
regulatory effect of HOTTIP among members of the
HOXA cluster was on HOXA13 expression. To deter-
mine whether HOTTIP promotes PDAC progression by
regulating HOXA13, we next employed siRNA to spe-
cifically silence the expression of HOXA13 in MIA
PaCa-2 and SW1990 cells (Figure 6A,B). Strikingly,
down-regulation of HOXA13 also inhibited PDAC cell
growth (Figure 6C,D), invasion (Figure 6E,F), and EMT
(Figure 6G-K). Taken together, these results suggest that
the regulatory function of HOTTIP in PDAC biology acts,
at least in part, by controlling HOXA13.HOXA13 overexpression correlates with poor survival in PDAC
To determine the clinical relevance of the HOTTIP-
HOXA13 axis in PDAC, levels of HOXA13 protein were
measured in 90 paraffin-embedded, human PDAC sam-
ples by immunohistochemistry. As described in the
Methods, the expression of HOXA13 was evaluated in
terms of intensity and percentage separately, and finally
expressed as a score of 0, 1, 2, or 3. In the present study,
only one PDAC tissue specimen was designated a score
of 0 (total negative staining) (Figure 7A). The scoring
diagram from 1 to 3 is shown in Figure 7B, and represen-
tative images of score 1, score 2, and score 3 are shown in
Figure 7C. We also analyzed the relationship between the
intensity of HOXA13 staining and clinicopathologic fea-
tures. Statistical analysis revealed that HOXA13 overex-
pression was correlated with lymph node metastasis and
poor histological differentiation (Table 1). Furthermore,
survival analysis revealed that higher HOXA13 staining
intensity correlated with poorer prognosis in PDAC pa-
tients (Figure 7D).
Discussion
The prognosis of PDAC is extremely poor, therefore,
understanding the mechanisms underlying PDAC patho-
genesis may help yield novel biomarkers for early detec-
tion and treatment [8]. Recent studies have shown that
dysregulated expression of lncRNAs in solid cancers re-
flect disease progression and may independently predict
patient outcome [22,23]. In the present study, we dem-
onstrate that a lncRNA HOXA transcript at the distal
tip (HOTTIP, is associated with PDAC tumor progres-
sion and disease outcome.
Rinn and coworkers have identified up to 3000 lncRNAs
[28,29], and biological characterization of these demon-
strates that lncRNAs are master regulators of embryonic
pluripotency, differentiation, and body axis patterning. In
addition, lncRNAs have been shown to promote develop-
mental transitions and regulate histone modifications and
hence influence the epigenetic programs of the transcrip-
tome [30,31]. Of note, lncRNAs may also play roles as
drivers of tumor suppression or exert oncogenic functions
in a wide variety of cancer types, by sustaining tumor cell
Figure 5 HOTTIP knockdown inhibits HOXA13 expression. (A) (B) MIA PaCa-2 and SW1990 cells were transduced with control shRNA or
shRNA against HOTTIP as indicated. Knockdown of HOTTIP abrogated the expression of HOXA genes in the PDAC cell lines, with the strongest
inhibition observed for HOXA13. (C) The effect of HOTTIP knockdown on HOXA13 protein levels was evaluated by western blotting. (D) The effect
of HOTTIP on HOXA13 expression was measured by immunofluorescence. (E) HOXA13 expression levels were examined in the above-mentioned
paired PDAC tissues and their adjacent non-neoplastic tissues by PCR. (F) Correlation scatterplot (Spearman test) of HOTTIP and HOXA13
expression in PDAC (middle panel; B2) compared with para-tumor (right panel; B3) areas of the above tested tissues.
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cative immortality, inducing angiogenesis, and promoting
invasion and metastasis [32-34].To date, many transcribed lncRNAs have been implicated
in gene silencing [35,36], but the potential roles of lncRNAs
in gene activation are much less understood [28,37].
Figure 6 (See legend on next page.)
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Figure 6 HOXA13 partly mediates the effect of HOTTIP on PDAC biology. (A) MIA PaCa-2 and SW1990 cells were transfected with control
siRNA or siRNA against HOXA13, and HOXA13 expression was subsequently determined by qRTPCR. (B) HOXA13 knockdown efficiency was also
confirmed by western blotting. (C) (D) Cell viability of MIA PaCa-2 (C) and SW1990 cells (D) was determined at the indicated time points by
CCK-8 assays. (E). Effect of HOXA13 on cell invasion ability was measured by Transwell assays. (F). The number of invading cells was analyzed.
(G) (H) The expression levels of EMT-related genes (E-cadherin, Vimentin, and Snai1) was evaluated by qRT-PCR 48 h after transfection in both
cell lines. (I) (J) The effect of HOXA13 silencing on E-cadherin, Vimentin, and Snail 1 protein levels was confirmed by western blotting. (K)
Immunofluorescence staining for the EMT makers in SW1990 cells. Data represent the mean ± s.d. from three independent experiments.
**p < 0.01, Student’s t-test.
Figure 7 HOXA13 overexpression correlates with poor survival in PDAC. (A) A representative field of one PDAC specimen with a HOXA13
staining score of 0. (B) The scoring sketch for HOXA13 staining in PDAC tissues (score 1-score 3). (C) Representative images of HOXA13 staining
in PDAC tissues (score 1-score 3). (D) Kaplan–Meier survival curves for patients with different HOXA13 staining scores in 90 cases of PDAC patients
(The case got score 0 was classified into group of score 1; removing the case alone does not affect the statistical difference of survival analysis).
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Table 1 Correlation of HOXA13 expression and
clinicopathological characteristics
Factor HOXA13 IHC scores P value*
1 (n=25)¶ 2 (n=31) 3 (n=34)
Age <60 12 17 17 0.867
≥60 13 14 17
Sex Male 15 20 22 0.920
Female 10 11 12
Differentiation Well 15 12 6 0.0039
Moderate 6 14 15
Poor 4 5 13
UICC stage pI 6 11 8 0.496
pII 19 20 26
T stage T1 6 3 6 0.645
T2 7 13 12
T3 12 15 16
N stage N0 16 12 9 0.014
N1 9 19 25
Perineural
invasion
Negative 11 16 19 0.664
Positive 14 15 15
¶For convenience, the case get score 0 was included in the group of score 1;
removing the case of score 0 alone does not affect the statistical differences in
any event.
*Pearson Chi-Square test.
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the 5′ tip of the HOXA locus and coordinates the activa-
tion of multiple 5′ HOXA genes in vivo [24], has been
identified as one of 231 lncRNAs associated with the
human HOX loci [28]. This lncRNA directly binds the
adaptor protein WDR5 and targets WDR5/MLL com-
plexes across HOXA, thus driving histone H3 lysine 4 tri-
methylation and gene transcription [24]. Furthermore,
expression of HOTTIP has been identified as a negative
prognostic factor in hepatocellular carcinoma patients
[25]; however, the functional role of HOTTIP in cancer
progression remains unknown. This present study offers
the first insight into the effect of HOTTIP on malignant
cell behavior. Our results demonstrate that HOTTIP,
which is overexpressed in human pancreatic cancer tissues
and cells compared with non-tumoral tissues and cell
lines, enhances pancreatic cell proliferation and invasion
as well as EMT. In addition, we show that targeted silen-
cing of HOTTIP potentiates the antitumor effects of
gemcitabine both in vitro and in vivo.
The HOX family of homeobox genes encodes tran-
scriptional regulators that are expressed during develop-
ment in regionalized domains along the main body axis
(limb, lung, gut, and lower genitourinary tract), where
they regulate cell proliferation and differentiation [38].
Additionally, HOX genes represent the most repeat-poorregions within the human genome and display a unique
gene network organization (four chromosomal loci: A, B,
C, and D). The HOXA locus consists of a cluster of 11
HOX genes with a graded expression pattern along body
appendages from proximal (close to the main body) to
distal (appendage tip) [39,40]. Among the HOXA genes,
HOXA13, which is a marker of gut primordial posteriori-
zation during development [41], has been shown to play a
crucial role in tumorigenesis of the liver and bladder and
in esophageal cancer [42-44]. In the present study,
HOXA13 was the most significantly inhibited gene within
the HOXA locus following depletion of HOTTIP in pan-
creatic cancer cells. Located in physical continuity (chr7p
15.2) with the HOXA13 gene [24], HOTTIP is expressed
from development to adulthood in lumbosacral anatomc
regions, explaining this regulatory relationship. Our obser-
vation is also in agreement with previously published data
conducted in fibroblasts from a distal anatomic site (fore-
skin) [24]. Moreover, we found that HOTTIP and HOXA13
expression was strongly positively correlated in 90 PDAC
tissues and in their corresponding adjacent nonneoplastic
tissues. In addition, siRNA-mediated HOXA13-knockdown
inhibited the proliferation, invasion, and EMT of PDAC
cells, which was consistent with the functional changes that
occurred after silencing the expression of HOTTIP in
PDAC cells. In addition to the HOTTIP-targeted regulation
of HOXA13 expression, we also observed reduced HOT-
TIP levels upon siRNA-mediated knockdown of HOXA13
in two different pancreatic cancer cell lines. Targeted inhib-
ition of HOXA13 in SW1990 cells led to a 77% reduction
in the mRNA level of HOXA13, and HOTTIP expression
was also reduced by 48.2%. Similarly, in MIA PaCa-2 cells,
HOXA13 levels were reduced to 29.3%, with a concomitant
39.6% reduction in HOTTIP levels. Our data are consistent
with a pioneering study demonstrating that decreased ex-
pression of HOXA13 led to a clear reduction of HOTTIP
expression in liver cancer-derived cell lines [26]. Thus, our
work confirms that the regulatory loop between HOTTIP
and its target, HOXA13, is also preserved during pancreatic
cancer tumorigenesis. Taken together, our results support a
mechanism whereby the HOTTIP/HOXA13 axis plays a
critical role in PDAC tumorigenesis. Analysis of the
relationship between HOXA13 expression in paraffin-
embedded PDAC samples and clinicopathological data
indicates that patients with high HOXA13 expression
exhibit increased lymph node metastasis, poor histological
differentiation, and decreased overall survival (Table 1,
Figure 5). Hence, our findings are clinically and function-
ally relevant to the progression of human PDAC.
Conclusions
Overall, our present study demonstrates that HOTTIP,
which is significantly overexpressed in PDAC, plays a
significant role in PDAC progression and gemcitabine
Li et al. Journal of Translational Medicine  (2015) 13:84 Page 15 of 16chemoresistance. Our results also show that HOTTIP
exerts its function in PDAC at least partly by controlling
HOXA13. Further studies are required to validate the
molecular axis involving HOTTIP and HOXA13 as a
predictive biomarker, as well as a therapeutic target in
PDAC. A deeper understanding of the function and down-
stream signaling pathways influenced by HOTTIP/HOXA13
deregulation may provide novel insights into the mecha-
nisms underlying PDAC tumorigenesis.
Additional file
Additional file 1: Figure S1. (A). Correlation scatterplot (Spearman test)
of HOTTIP and HOXA13 expression in the eight PDAC samples used for
microarray compared with their paired para-tumor tissues.(B). HOXA13
expression was evaluated in five pancreatic cancer cell lines compared
with HPDE6 cells via qRT-PCR. mRNA levels were normalized to β-actin.
HOTTIP levels in these cell lines are also shown (the same data as
described in Figure 1C). (C). The correlation between HOTTIP and HOXA13
mRNA expression in five pancreatic cancer cell lines was evaluated using
Spearman correlation analysis.
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